Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.
Study to evaluate effectiveness of hypoglossal nerve stimulation
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
The joint initiative is called J-ARC Healthcare Solutions
Subscribe To Our Newsletter & Stay Updated
